Dr. Lal PathLabs Reports 10.7% Revenue Growth in Q2 FY26

Dr. Lal PathLabs Limited (referred to as the “Company”, a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended September 30, 2025.

Consolidated Performance Highlights: Q2 FY26 vs Q2 FY25

• Revenue increased by 10.7% in Q2 FY26 and FH26 by 11.0%

• EBITDA increased by 10.8% with a margin of 30.7%

• PAT increased by 16.4% with a margin for of 20.8%  

• Interim Dividend of Rs. 7 per share for Q2 FY26

• Board has approved bonus issue in the ratio of 1:1 i.e. 1 Bonus share for every 1 share held on record date

Financial Overview (Consolidated) in Rs Cr